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Abstract
Background: Linezolid, an oxazolidinone, substantially improves treatment outcomes of multidrug-resistant tuberculosis
and extensively drug-resistant tuberculosis. We started a trial to test whether the use of linezolid instead of ethambutol
could increase the rate of sputum culture conversion as of 8 weeks of treatment in patients with drug-susceptible
tuberculosis.
Methods/design: This is a phase II, multicenter, randomized study with three arms. We are enrolling patients
with pulmonary tuberculosis without rifampicin resistance screened by the Xpert MTB/RIF® assay. The standard
treatment arm uses isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and ethambutol (2 months).
Experimental arm 1 uses linezolid (600 mg/day) for 4 weeks instead of ethambutol. Experimental arm 2 uses linezolid
(600 mg/day) for 2 weeks instead of ethambutol. The primary outcome is the sputum culture conversion rate on liquid
media after 2 months of treatment. Secondary outcomes include the sputum culture conversion rate on solid media
after 2 months of treatment, time to sputum culture conversion on liquid and solid media, cure rate, and treatment
success rate. The frequencies of total adverse events (AEs) and serious AEs will be described and documented. Based
on an α = 0.05 level of significance, a power of 85%, a 15% difference in the culture conversion rate after 2 months
between the control arm and experimental arm 1 (75% vs. 90%), a 10% default (loss to follow-up) rate, and a 10%
culture failure, the required number per arm was calculated to be 143 (429 in total).
Discussion: This trial will reveal the effectiveness and safety of 2 or 4 weeks of use of linezolid instead of ethambutol for
patients with drug-susceptible pulmonary tuberculosis. If a new regimen including linezolid shows a higher culture
conversion rate by week 8, and is safe, it could be tested as a 4-month antituberculosis treatment regimen in the future.
Trial registration: ClincalTrials.gov, NCT01994460. Registered on 13 November 2013.
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Background
Tuberculosis (TB) is a major challenge for the main-
tenance of human health. In 2014, there were 9.6 mil-
lion new cases of TB, including 5.4 million men, 3.2
million women, and 1.0 million children. TB killed
1.5 million people in 2014 [1].
The current standard short-course treatment for pul-
monary TB requires 6 months to complete. This long
treatment duration increases the likelihood of adverse
effects while decreasing patients’ adherence to anti-TB
drugs. As many as 16.8% of patients with TB who were
treated with the 6-month regimen showed poor compli-
ance [2]. Patients with TB who take their medication
irregularly could spread TB to others, and/or their con-
dition could progress to drug-resistant TB. A new,
shorter duration anti-TB treatment regimen could de-
crease the frequency of this poor compliance.
Linezolid, an oxazolidinone, exerts antibacterial activ-
ity via inhibiting protein synthesis by binding the 23S
ribosomal RNA portion of the bacterial 50S ribosomal
subunit [3]. Linezolid has shown modest early bacteri-
cidal activity against Mycobacterium tuberculosis [4, 5].
However, adding linezolid has resulted in a culture
conversion rate of 89% by 6 months in patients with
extensively drug-resistant TB (XDR-TB) refractory to
previous treatment [6].
Considering its impressive anti-TB effect, linezolid
could also have additive activity when administered
along with existing anti-TB drugs in patients with drug-
susceptible pulmonary TB. We hypothesize that the use
of linezolid instead of ethambutol will increase the
culture conversion rate by week 8.
Methods/design
Setting
This randomized controlled trial is to be conducted
at four hospitals in South Korea. The flow diagram of
the trial is shown in Fig. 1. Three of the hospitals are
affiliated with the Seoul National University College
of Medicine (Seoul National University Hospital,
Seoul National University Bundang Hospital, and
Seoul National University Boramae Medical Center),
and the other is the National Medical Center in Seoul. All
hospitals are located in an urban area.
Design
This is a phase II, multicenter, randomized study with
three arms. Eligible patients are first screened by safety
laboratory testing and using the Xpert MTB/RIF® assay
(Cepheid, Sunnyvale, CA, USA) for rifampicin resistance.
Patients with TB without resistance to rifampicin are
randomized to the following three arms at a 1:1:1 ratio:
1. Arm 1 (control arm): Standard treatment for drug-
sensitive pulmonary TB uses isoniazid (6 months),
rifampicin (6 months), pyrazinamide (2 months),
and ethambutol (2 months) as recommended by the
Korean National Guidelines [7] (Table 1).
2. Arm 2 (experimental arm 1): Treatment using isoniazid
(6 months), rifampicin (6 months), pyrazinamide
(2 months), and linezolid is used (600 mg/day, 4 weeks).
3. Arm 3 (experimental arm 2): Treatment using
isoniazid (6 months), rifampicin (6 months),
pyrazinamide (2 months), and linezolid is used
(600 mg/day, 2 weeks).
The study timeline is shown in Table 2. Returned trial
product is reconciled at every visit by the research nurse
to ensure adherence to the allocated regimen. If a par-
ticipant misses a scheduled visit, the research nurse
makes immediate phone contact. The duty physician
makes a decision on discontinuation or modification of
the allocated regimen for patients showing clinical de-
terioration or reporting adverse events associated with
the anti-TB treatment. No treatment or intervention is
prohibited for the participants, and any ancillary and/or
post-trial care is determined by the duty physician.
Outcomes
The primary outcome is the proportion of participants with
sputum culture conversion on liquid media after 2 months
of treatment. Secondary outcomes include the proportion
of participants with sputum culture conversion on solid
media after 2 months of treatment, the interval from enroll-
ment to sputum culture conversion on liquid and solid
media, the proportion of cured participants, and the pro-
portion of participants with a treatment success rate.
Definitions
Culture conversion and rate of culture conversion
We define culture conversion as two consecutive nega-
tive sputum cultures on liquid or on solid media. The
date of culture conversion is defined as the date of the
initial negative culture. Negative sputum cultures followed
by contaminated cultures are also regarded as culture con-
version. Culture conversion is also defined as a case where
the participant cannot expectorate sputum after one nega-
tive sputum culture.
Treatment outcomes
We define treatment outcomes according to the Korean
TB Guidelines as follows [7]:
 Cure: We define cure as a negative sputum culture
after (or during the last months of ) treatment
combined with one or more prior negative
sputum cultures.
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 Treatment completed: We define treatment
completed as (1) a negative sputum culture after or
at the end of treatment, but without a prior negative
sputum culture or (2) a negative sputum culture
during treatment, but the lack of a negative sputum
culture after or during the last month of treatment.
 Treatment success: We define treatment success as
achievement of a cure or treatment completion.
Eligibility criteria for participants
Participants with pulmonary TB satisfying the inclusion
criteria are enrolled competitively by investigators in the
outpatient clinic as well as the inpatient setting in the
four participating hospitals. The inclusion criteria are as
follows: men and women aged from 20 to 80 years, with
documented sputum Xpert MTB/RIF® assay-positive
pulmonary TB at screening, and administration of
current TB therapy (if any) for ≤7 days at the time of
enrollment.
Patients will be excluded if they have HIV/AIDS. Female
patients of childbearing potential who are pregnant,
breastfeeding, or unwilling to avoid pregnancy will also be
excluded. Additionally, any of the following factors will
lead to exclusion: (1) absolute neutrophil count of <2000
cells/mL, (2) white blood cell count of <3.0 × 103/μL, (3)
hemoglobin levels of <7.0 g/dL, (4) serum creatinine levels
of >2.0 mg/dL, (5) aspartate aminotransferase levels of
>100 IU/L, (6) alanine aminotransferase levels of >100
Table 1 Dose and schedule of first-line anti-TB drugs recommended by the Korean National Guidelines [7]
Drug Dosage Frequency and timing
Dose/kg Recommended dose Maximal dose
Isoniazid 5 mg/kg 300 mg/day 300 mg/day Daily, before meal
Rifampicin 10 mg/kg 450 mg (<50 kg) 600 mg/day Daily, before meal
600 mg (≥50 kg)
Pyrazinamide 20–30 mg/kg 1000 mg (<50 kg) Daily, before or after meal
1500 mg (50–70 kg)
2000 mg (>70 kg)
Ethambutol 15–20 mg/kg 800 mg (<60 kg) Daily, before or after meal
1200 mg (60–80 kg)
1600 mg (>80 kg)
Fig. 1 Flow diagram of the trial
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IU/L, (7) total bilirubin levels of >2.0 mg/dL, (8) history
of optic neuritis or peripheral neuropathy, and (9) other
significant laboratory abnormalities (i.e., absolute neutro-
phil count, creatinine levels). Finally, we also exclude pa-
tients with the need for ongoing therapy with selective
serotonin reuptake inhibitors, tricyclic antidepressants,
serotonin 5-hydroxytrptamine 1 receptor agonists (trip-
tans), meperidine, buspirone, monoamine oxidase inhibi-
tors, sympathomimetic agents (e.g., pseudoephedrine),
vasopressive agents (e.g., epinephrine, norepinephrine), or
dopaminergic agents (e.g., dopamine, dobutamine).
Randomization
We assign participants to study arms using an adaptive
stratified sampling method to minimize the imbalance
between the numbers of participants in each treatment
group over a number of stratification factors: the institu-
tion, the presence/absence of cavitation on baseline
chest radiographs, and the presence/absence of baseline
diabetes mellitus. A centralized web-based system of
the Medical Research Collaborating Center of Seoul
National University Hospital is used for allocation.
Diabetes mellitus is defined by any one of the following:
(1) fasting plasma glucose levels ≥126 mg/dL, (2) random
plasma glucose levels ≥200 mg/dL, or (3) the presence of
any antidiabetic agent as a concomitant medicine.
Justification of sample size
The hypothesis of this study is that the use of linezolid
instead of ethambutol will increase the sputum culture
conversion rate on liquid media after 2 months of anti-
TB treatment. A primary comparison will be performed
between the control arm and experimental arm 1
(linezolid, 600 mg/day for 4 weeks).
Hypothesis for sample size calculation
Ho (null hypothesis): pt = pc (culture conversion rate
after 2 months of treatment is not different between the
Table 2 Study timeline
Visit Screening Baseline visita Treatment
Visit number 1 2 3 4 5 6 7 8 9 10
Weeks (w) −2 w to −1 d 0 1 w 2 w 4 w 8 w 12 w 16 w 20 w 24 w




Physical examination X X X X X X X X X
Neurologic examination X X X X X X X X X
Xpert MTB/RIF® assay X
Sputum AFB smear X Xd X X X X X X X X
TB culture (solid) X Xd X X X X X X X X
TB culture (liquid) X Xd X X X X X X X X
DSTb With first cultured Mycobacterium tuberculosis
CXR X Xd X X X X X X
HIV, HBV X
Total bilirubin, AST/ALT, creatinine X Xd X X X X X X X X
Complete blood count X Xd X X X X X X X X
Optic test X X X X X
Urine HCGc X
Compliance of drug intake X X X X X X X X
Adverse drug reaction X X X X X X X X
Other medicationse X X X X X X X X X
w weeks, d days, NA not applicable, AFB acid-fast bacilli, TB tuberculosis, DST drug susceptibility test, CXR simple chest radiography, HIV human immunodeficiency
virus, HBV hepatitis B virus, AST aspartate transaminase, ALT alanine transaminase, HCG human chorionic gonadotropin
aTreatment will be initiated at the baseline visit, as TB treatment should be started promptly following diagnosis
bDrug susceptibility test for isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, kanamycin, amikacin, capreomycin, ofloxacin, levofloxacin, moxifloxacin,
prothionamide, cycloserine, and para-aminosalicylic acid
cOnly in females of childbearing potential
dCan be omitted if the results of previous tests within the prior 4 weeks are available
eIn particular, immunosuppressive agents (including corticosteroids)
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control arm and experimental arm 1 [linezolid for 4
weeks]).
H1 (alternative hypothesis): pt ≠ pc (culture conversion
rate after 2 months of treatment is different between the
control arm and experimental arm 1 [linezolid for 4
weeks]).
Assumptions
The sputum culture conversion rate on liquid media
after 2 months in patients who are treated at Seoul
National University Hospital is approximately 75% [8].
We assume that there will be a 90% culture conversion
rate on liquid media after 2 months in experimental arm
1 (primary hypothesis) and a 10% default (loss to follow-
up) rate, and that 10% of participants will have a positive
Xpert MTB/RIF® assay result but a negative result for M.
tuberculosis culture.
Based on an α = 0.05 level of significance, a power of
85%, and a 15% difference in the culture conversion rate
after 2 months between the control arm and experimen-
tal arm 1 (75% vs. 90%), the sample size per arm was cal-
culated to be 114 (342 in total). After consideration of a
10% default rate and 10% culture failure in participants
with a positive Xpert MTB/RIF® assay result, the final
number per arm was calculated to be 143 (429 in total).
Statistical analysis
The results of this trial will be analyzed based primarily
on the intention-to-treat (ITT) approach. In addition, a
per protocol analysis will be performed secondarily. A
safety analysis will be performed based on the safety
group. The ITT groups will comprise participants who
satisfy the inclusion and exclusion criteria, those who
are randomized, and those who take the trial drug at
least once. The per protocol groups will comprise partic-
ipants from ITT satisfying the following conditions: (1)
participants took the trial drug (ethambutol or linezolid)
at greater than 80% of the planned dose (ethambutol,
≥45 days for control arm; linezolid, ≥23 days for experi-
mental arm 1; linezolid, ≥12 days for experimental arm
2), and (2) participants completed the clinical trial ac-
cording to the protocol. The safety group includes par-
ticipants who took the trial drug at least once. No
interim analysis of the data is planned.
Efficacy outcomes
Comparisons will be performed using two-tailed tests
with a statistical significance of 5%. A sensitivity analysis
will be carried out based on participants with no resist-
ance to rifampicin, isoniazid, ethambutol, or pyrazina-
mide. The primary comparison will be performed
between the control arm (arm 1) and experimental arm
1 (arm 2). The comparison between the control arm and
experimental arm 2 (arm 3) is solely investigational.
Analysis of primary outcome
For the primary outcome of this trial, a negative culture
conversion rate on liquid media after 2 months of treat-
ment, the culture conversion rate will be estimated as
the proportion with a 95% confidence interval for each
treatment group. The difference between the control
arm and experimental arm 1 (linezolid for 4 weeks) will
subsequently be determined using the chi-square test or
Fisher’s exact test.
Analysis of secondary outcomes
The analysis of secondary outcomes will be described as
explorative outcomes. The sputum culture conversion
rate after 2 months of treatment (solid media) among
the three groups will be compared using the chi-square
test or Fisher’s exact test. The median time to culture
conversion will be calculated in each group and com-
pared using a log-rank test. Cure rate, treatment com-
pletion rate, and treatment success rate will be
compared among the three groups using the chi-square
test or Fisher’s exact test.
Safety assessment
Grades 1 and 2 peripheral or optic neuropathies and any
grade 3 adverse events (AEs), according to the Common
Terminology Criteria for Adverse Events, that are con-
sidered possibly, probably, or definitely related to the re-
search, and all serious AEs, will be fully and completely
documented.
A safety analysis will be performed based on AEs that
are identified during the clinical trial. Frequencies and
fractions of total AEs, serious AEs, and AEs will be de-
scribed, together with 95% confidence intervals. In
addition, the relatedness of AEs to the trial drug and
their seriousness will be summarized. Frequencies of
grade 3 or 4 AEs and those of each AE will be compared
using the chi-square test or Fisher’s exact test.
Stratified analysis
Primary and secondary outcomes will be analyzed separ-
ately in participants with sputum smear-positive and
smear-negative pulmonary TB.
Data collection and management
This study will use a web-based electronic case report
form (eCRF) with Pharmaco-epidemiology and Clinical
Trial Application X (PhactaX). PhactaX has been devel-
oped by the Medical Research Collaborating Center of
Seoul National University Hospital in collaboration with
an outsourced contractor. PhactaX is based on Java and
Oracle databases, in compliance with international stan-
dards and regulations. The eCFR designed for this study
used dummy variables for user acceptance testing to
confirm its validity.
Lee et al. Trials  (2017) 18:68 Page 5 of 8
Fig. 2 Completed SPIRIT figure
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During the study, the field monitor will visit the sites
every 3 months to check the completeness of patient re-
cords, accuracy of eCRF entries, adherence to the proto-
col and to Good Clinical Practice, and enrollment
progress, and to ensure the correct storage, dispensing,
and accountability of the trial products.
Supervision of the trial
A data and safety monitoring board will consist of two
unblinded independent pulmonologists and one un-
blinded biostatistician. Based on data review during the
trial conduct, the board may provide recommendations
such as protocol amendment, continuation, or stopping
of the trial.
Confidentiality
We will collect the protected health information of study
participants only when necessary to evaluate the efficacy,
safety, and tolerability of the study medication used in
this trial. Under privacy rules and relevant data security
rules and safety guidelines, the investigators will care-
fully collect and use the protected health information of
study participants. Paper files containing participants’
data (including personally identifiable information and
copies of the signed consent forms) will be securely
stored in a locked office on campus in locked filing
cabinets. Digital files containing participants’ data will be
stored in password-protected files on university-
maintained servers. Access to study files will be re-
stricted to authorized personnel only.
The items in the present study protocol comply with
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist (see the SPIRIT
Checklist and figure in Additional file 1 and Fig. 2).
Discussion
Development of a shorter duration anti-TB treatment
regimen could improve not only treatment outcomes of
individual patients but also TB control throughout the
world. Based on higher culture conversion rates after 2
months of treatment in drug-susceptible TB patients
treated with regimens, including moxifloxacin [9, 10],
4-month regimens, including moxifloxacin or gatifloxa-
cin, have been attempted recently. The REMoxTB trial
replaced isoniazid or ethambutol with moxifloxacin [11].
The OFLUOTUB trial used gatifloxacin instead of eth-
ambutol [12]. The RIFAQUIN trial included moxifloxa-
cin instead of isoniazid in the intensive phase and used
twice-weekly application of moxifloxacin and rifapentine
in the continuation phase [13]. Another trial tested
three-times-weekly administration of isoniazid, rifampi-
cin, pyrazinamide, and moxifloxacin or gatifloxacin in-
stead of ethambutol [14]. Unfortunately, none of these
4-month treatment regimens showed non-inferiority to a
6-month regimen.
Based on the impressive effectiveness of linezolid in
patients with XDR-TB refractory to previous treatment
[6], we are performing a trial using linezolid instead of
ethambutol for drug-susceptible pulmonary TB. If a new
regimen including linezolid shows an excellent culture
conversion rate by week 8, which could be a surrogate
for relapse [15, 16], it could be tested as a 4-month anti-
TB treatment regimen through another clinical trial.
Safety issues of using linezolid for TB treatment will
also be addressed through the current trial. Although
linezolid is highly effective for the treatment of
multidrug-resistant TB, it is frequently accompanied by
serious AEs, including peripheral neuropathy and bone
marrow suppression. In a recent clinical trial of linezolid
in patients with XDR-TB, as many as 87% of patients re-
ported clinically significant AEs [6]. Similarly, a meta-
analysis reported AEs in 58.9% of multidrug-resistant or
XDR-TB patients who used linezolid [17]. These reports
of frequent AEs underscore the limitation of linezolid as
a standard drug for treatment of multidrug-resistant TB,
which mandates the long-term use of anti-TB drugs.
Our trial using linezolid for 2 or 4 weeks, times which
are within the permitted duration of use, will reveal the
safety of the relatively short-term use of linezolid for
patients with TB.
Finally, several issues should be considered once the
results of this trial become available. First, this trial is
being performed only in referral hospitals. The charac-
teristics of patients with TB diagnosed and treated in re-
ferral hospitals could differ from those of patients
treated in community hospitals. Second, we exclude
HIV/AIDS patients from this trial. The application of
trial results in areas with a high burden of HIV/AIDS
should, therefore, be approached with caution. Third,
this is an open-label trial, so the possibility of bias
should be taken into account when interpreting results.
Finally, if the usefulness of linezolid for drug-susceptible
TB is confirmed through this study, strategies to address
issues of cost and availability should be examined.
Trial status
Recruitment began at the first site in February 2014 and
is expected to be completed by July 2017.
Additional file
Additional file 1: SPIRIT checklist. (DOC 126 kb)
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